Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor

[Image: see text] The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1′ site binder into the lead compound 1 guided by structure-based drug design (SBDD), and fur...

Descripción completa

Detalles Bibliográficos
Autores principales: Imaeda, Yasuhiro, Tokuhara, Hidekazu, Fukase, Yoshiyuki, Kanagawa, Ray, Kajimoto, Yumiko, Kusumoto, Keiji, Kondo, Mitsuyo, Snell, Gyorgy, Behnke, Craig A., Kuroita, Takanobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066151/
https://www.ncbi.nlm.nih.gov/pubmed/27774132
http://dx.doi.org/10.1021/acsmedchemlett.6b00251
_version_ 1782460431034482688
author Imaeda, Yasuhiro
Tokuhara, Hidekazu
Fukase, Yoshiyuki
Kanagawa, Ray
Kajimoto, Yumiko
Kusumoto, Keiji
Kondo, Mitsuyo
Snell, Gyorgy
Behnke, Craig A.
Kuroita, Takanobu
author_facet Imaeda, Yasuhiro
Tokuhara, Hidekazu
Fukase, Yoshiyuki
Kanagawa, Ray
Kajimoto, Yumiko
Kusumoto, Keiji
Kondo, Mitsuyo
Snell, Gyorgy
Behnke, Craig A.
Kuroita, Takanobu
author_sort Imaeda, Yasuhiro
collection PubMed
description [Image: see text] The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1′ site binder into the lead compound 1 guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative 10 (1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound 10 demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound 10 is currently in clinical trials.
format Online
Article
Text
id pubmed-5066151
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-50661512017-09-12 Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor Imaeda, Yasuhiro Tokuhara, Hidekazu Fukase, Yoshiyuki Kanagawa, Ray Kajimoto, Yumiko Kusumoto, Keiji Kondo, Mitsuyo Snell, Gyorgy Behnke, Craig A. Kuroita, Takanobu ACS Med Chem Lett [Image: see text] The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1′ site binder into the lead compound 1 guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative 10 (1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound 10 demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound 10 is currently in clinical trials. American Chemical Society 2016-09-12 /pmc/articles/PMC5066151/ /pubmed/27774132 http://dx.doi.org/10.1021/acsmedchemlett.6b00251 Text en Copyright © 2016 American Chemical Society
spellingShingle Imaeda, Yasuhiro
Tokuhara, Hidekazu
Fukase, Yoshiyuki
Kanagawa, Ray
Kajimoto, Yumiko
Kusumoto, Keiji
Kondo, Mitsuyo
Snell, Gyorgy
Behnke, Craig A.
Kuroita, Takanobu
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
title Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
title_full Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
title_fullStr Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
title_full_unstemmed Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
title_short Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
title_sort discovery of tak-272: a novel, potent, and orally active renin inhibitor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066151/
https://www.ncbi.nlm.nih.gov/pubmed/27774132
http://dx.doi.org/10.1021/acsmedchemlett.6b00251
work_keys_str_mv AT imaedayasuhiro discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT tokuharahidekazu discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT fukaseyoshiyuki discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT kanagawaray discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT kajimotoyumiko discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT kusumotokeiji discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT kondomitsuyo discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT snellgyorgy discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT behnkecraiga discoveryoftak272anovelpotentandorallyactiverenininhibitor
AT kuroitatakanobu discoveryoftak272anovelpotentandorallyactiverenininhibitor

Ejemplares similares